Modern Pharmacotherapy and Multidisciplinary Advances in Obesity Management

To the Editor,

The purpose of this correspondence is to draw focused attention to the evolving therapeutic paradigm in obesity management and to highlight how multidisciplinary strategies, including emerging pharmacotherapies, are redefining both short- and long-term outcomes. This letter builds upon recent clinical evidence and incorporates our observations from patient-centered programs exploring pharmacological–behavioral integration in obesity care.

Obesity has rapidly evolved into one of the most formidable health challenges of the 21st century, affecting more than one billion people globally and accounting for over half of the adult population in several countries.[1,2] Its increasing prevalence is driven by sedentary lifestyles, dietary transitions, and complex socioeconomic determinants. While this epidemic has been well characterized, the dynamic advances in treatment – particularly in pharmacotherapy and digital integration – deserve renewed attention.

Insights from multidisciplinary obesity clinics indicate that the integration of pharmacotherapy with behavioral modification substantially enhances patient adherence and weight-maintenance success. However, there remains a striking knowledge gap among clinicians regarding patient selection, dose titration, and long-term follow-up in the context of novel drugs. The purpose of this letter is, therefore, to emphasize the translational importance of recent pharmacologic developments and to advocate for practical strategies that merge these therapies with lifestyle and digital support systems.

The therapeutic landscape has shifted dramatically with glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, and dual GIP/GLP-1 agonists like tirzepatide, which have shown unprecedented efficacy in weight reduction.[1-3] In the STEP-1 trial, semaglutide led to a 14.9% reduction in body weight, and tirzepatide demonstrated reductions approaching 20.9% in the SURMOUNT program.[3] These results move antiobesity treatment into the realm once reserved for bariatric surgery.

Beyond their quantitative success, these drugs deliver cardiometabolic improvements – reduced blood pressure, improved lipid profiles, and decreased inflammatory markers – thereby addressing obesity as a systemic disorder rather than a cosmetic concern. Importantly, the SELECT trial confirmed semaglutide's 20% reduction in major cardiovascular events among individuals with obesity and established atherosclerosis.[2]

The ongoing clinical development of oral GLP-1 analogs, such as orforglipron and multiagonist molecules, such as retatrutide, is paving the way for an exciting new era in pharmacology. Reviews and early assessments of patient preferences indicate that these oral medications could greatly enhance adherence, especially among nondiabetic individuals.[1,3] These innovations highlight the direction toward precision obesity medicine, where pharmacological response may be guided by genetic and metabolic phenotyping.

Pharmacotherapy alone cannot address the behavioral and psychosocial dimensions of obesity. Evidence from published literature on patient-support programs[1,3] suggests that coupling GLP-1-based therapy with digital adherence tools and tele-counseling improves continuity of care and minimizes relapse. Mobile applications now provide real-time monitoring of medication schedules, caloric tracking, and behavioral reinforcement – an area warranting further research collaboration among clinicians and data scientists.

Despite these therapeutic milestones, global inequity in obesity treatment persists. In the United States, fewer than 6% of eligible adults without diabetes received any pharmacologic obesity treatment between 2022 and 2023.[4] In developing nations, cost barriers, lack of awareness, and regulatory delays further widen the treatment gap. To ensure the public-health impact of these medical advances, affordable formulations, national obesity registries, and inclusion of antiobesity therapy in public insurance programs should be prioritized.

This letter underscores the need for integrating modern pharmacotherapy into comprehensive, multidisciplinary obesity management. The field has entered a transformative phase where dual-and tri-agonist therapies, supported by behavioral and digital interventions, can achieve sustainable weight loss and improve cardiometabolic health. Insights from emerging data and clinical observations reinforce that the success of pharmacological innovation will depend not merely on molecular discovery but on its thoughtful implementation within personalized, equitable, and technology-enabled care models.

While obesity remains a multifactorial disease, the convergence of science, technology, and clinical empathy is redefining its management paradigm, heralding a new era of therapeutic optimism.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Roopesh Jain, Archana Tiwari

School of Biomolecular Engineering and Biotechnology, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India

Address for correspondence: Dr. Roopesh Jain,
School of Biomolecular Engineering and Biotechnology,
Rajiv Gandhi Proudyogiki Vishwavidyalaya, Airport Road, Gandhi Nagar, Bhopal,
Madhya Pradesh, India.
E-mail: science.roopesh@gmail.com

Submitted: 09-10-2025 **Revised:** 08-11-2025
Accepted: 01-12-2025 **Published:** 31-12-2025

References

1. Fredrick TW, Camilleri M, Acosta A. Pharmacotherapy for obesity: Recent updates. Clin Pharmacol 2025;17:305-27.
2. Janić M, Janež A, El-Tanani M, Rizzo M. Obesity: Recent advances and future perspectives. Biomedicines 2025;13:368.
3. le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, Machineni S, *et al.* Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring) 2023;31:96-110.
4. Wojtara M, Mazumder A, Syeda Y, Mozgała N. Glucagon-like peptide-1 receptor agonists for chronic weight management. Adv Med 2023;2023:9946924.

Access this article online

Quick Response Code:

Website: https://journals.lww.com/BVMJ/

DOI: 10.4103/BVMJ.BVMJ_111_25

How to cite this article: Jain DR, Tiwari A. Modern pharmacotherapy and multidisciplinary advances in obesity management. Bhar Vid Med J 2025;5:227-8.